
    
      This is a phase I single arm, open label, multi-center (3 participating sites) dose
      escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4
      weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of
      bortezomib 1.3 mg/m2 administered as a short intravenous (IV) infusion of 3-5 seconds every
      week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior
      to the oral dose of panobinostat. There will be sub-investigators participating in this study
      who will enroll at sub-sites.
    
  